Abstract
The IGF system plays a major role in growth, development and maintenance of homeostasis in normal cells and also contributes towards proliferation of malignant cells. Any disruption in the IGF system has its implications on growth retardation, atherosclerosis, insulin resistance and cancer. Imbalances in the IGF axis are known to contribute towards the progression of breast cancer. Due to the ubiquitous nature of the components of the IGF system, targeting specific members of the axis has gained attention over the past decades. The most elaborately investigated component as a therapeutic target in the system is the IGF-IR and studies have been pursued to inhibit IGF-IR by the administration of monoclonal antibodies and tyrosine kinase inhibitors. Very recently, a novel cell death receptor that binds specifically to IGFBP-3 was identified. It has also been shown that the IGFBP-3/IGFBP-3 receptor may be impaired in breast and prostate cancer. In this review, we present the mechanisms used to target the IGF system in various diseased states, emphasizing on breast cancer. We further discuss currently available therapeutic approaches and summarize the latest patents published in the field of IGF-I/IGF-IR and IGFBP-3/IGFBP-3R systems.
Keywords: Anti-cancer drugs, breast cancer, IGF system, IGF-IR, IGFBP-3, IGFBP-3R, tyrosine kinase inhibitors, patents, ENDOCRINE DISORDERS, cancer therapy, homeostasis
Recent Patents on Anti-Cancer Drug Discovery
Title: Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Volume: 6 Issue: 2
Author(s): Lathika Mohanraj and Youngman Oh
Affiliation:
Keywords: Anti-cancer drugs, breast cancer, IGF system, IGF-IR, IGFBP-3, IGFBP-3R, tyrosine kinase inhibitors, patents, ENDOCRINE DISORDERS, cancer therapy, homeostasis
Abstract: The IGF system plays a major role in growth, development and maintenance of homeostasis in normal cells and also contributes towards proliferation of malignant cells. Any disruption in the IGF system has its implications on growth retardation, atherosclerosis, insulin resistance and cancer. Imbalances in the IGF axis are known to contribute towards the progression of breast cancer. Due to the ubiquitous nature of the components of the IGF system, targeting specific members of the axis has gained attention over the past decades. The most elaborately investigated component as a therapeutic target in the system is the IGF-IR and studies have been pursued to inhibit IGF-IR by the administration of monoclonal antibodies and tyrosine kinase inhibitors. Very recently, a novel cell death receptor that binds specifically to IGFBP-3 was identified. It has also been shown that the IGFBP-3/IGFBP-3 receptor may be impaired in breast and prostate cancer. In this review, we present the mechanisms used to target the IGF system in various diseased states, emphasizing on breast cancer. We further discuss currently available therapeutic approaches and summarize the latest patents published in the field of IGF-I/IGF-IR and IGFBP-3/IGFBP-3R systems.
Export Options
About this article
Cite this article as:
Mohanraj Lathika and Oh Youngman, Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489211795328512
DOI https://dx.doi.org/10.2174/157489211795328512 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Activity of N-Sulfonylamides of Tripeptides as Potential Urokinase Inhibitors
Protein & Peptide Letters Germ Cell Apoptosis: Relevance to Infertility and Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Recent Progress in Synthesis and Applications of Fluorinated Carbohydrates
Current Organic Chemistry Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Editorial [Hot Topic: An Up-Date of Olive Oil and Bioactive Constituents in Health: Molecular Mechanisms and Clinical Implications (Executive Guest Editor: Catalina Alarcon de la Lastra Romero)]
Current Pharmaceutical Design Achieving Detumescence of Ischemic Priapism with Intra-Cavernosal Injection of entanyl: An Unexpected Outcome of Miscommunication Error
Current Drug Safety Oxidation Inhibits Iron-Induced Blood Coagulation
Current Drug Targets Preface
Recent Patents on Anti-Cancer Drug Discovery Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and Lenalidomide, Experimental and Therapeutic Applications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Current Cancer Drug Targets Editorial (Thematic Issue: Novel Therapeutic Strategies for Castration-resistant Prostate Cancer: Update and Future Perspectives)
Clinical Cancer Drugs Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Analytical Characterization of Label-Free Immunosensor Subsystems Based on Multi-Walled Carbon Nanotube Array-Modified Gold Interface
Combinatorial Chemistry & High Throughput Screening Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics Mass Spectrometric Imaging of the Nervous System
Current Pharmaceutical Design Topical Delivery of Antioxidants
Current Drug Delivery Understanding Cancer Drug Resistance by Developing and Studying Resistant Cell Line Models
Current Cancer Drug Targets